
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Under the Securities Exchange Act of 1934

(Amendment No. 7)*

Core Scientific, Inc.

(Name of Issuer)

Common Stock, par value \$0.00001 per share

(Title of Class of Securities)

21874A106

(CUSIP Number)

John O'Callaghan
Two Seas Capital LP, 32 Elm Place, 3rd Floor
Rye, NY, 10580
(914) 690-8253

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/18/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

21874A106

1	Name of reporting person Two Seas Capital LP
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	SEC use only

4	Source of funds (See Instructions) AF	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 20,697,679.00
	8	Shared Voting Power 0.00
	9	Sole Dispositive Power 20,697,679.00
	10	Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 20,697,679.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>	
13	Percent of class represented by amount in Row (11) 6.7 %	
14	Type of Reporting Person (See Instructions) IA, PN	

SCHEDULE 13D

CUSIP No.	21874A106
-----------	-----------

1	Name of reporting person Two Seas Capital GP LLC
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6	Citizenship or place of organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 20,697,679.00
	8	Shared Voting Power 0.00
	9	Sole Dispositive Power 20,697,679.00
	10	Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 20,697,679.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>	
13	Percent of class represented by amount in Row (11) 6.7 %	
14	Type of Reporting Person (See Instructions) HC, OO	

SCHEDULE 13D

CUSIP No.	21874A106
-----------	-----------

1	Name of reporting person Sina Toussi
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6	Citizenship or place of organization UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 20,697,679.00
	8	Shared Voting Power 0.00
	9	Sole Dispositive Power 20,697,679.00
	10	Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 20,697,679.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>	
13	Percent of class represented by amount in Row (11) 6.7 %	
14	Type of Reporting Person (See Instructions) IN, HC	

SCHEDULE 13D

Item 1. Security and Issuer

- (a) **Title of Class of Securities:**
Common Stock, par value \$0.00001 per share
- (b) **Name of Issuer:**
Core Scientific, Inc.
- (c) **Address of Issuer's Principal Executive Offices:**
838 Walker Road, 21-2105, Dover, DELAWARE , 19904.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is hereby amended and restated as follows:

The aggregate purchase price of the 2,531,902 shares of Common Stock directly held by the Strategic Fund reported herein was \$34,502,799.86. The aggregate purchase price of the 12,949,276 shares of Common Stock, 44,650 options to purchase Common Stock and 313,646 warrants directly held by the Global Fund reported herein was \$147,244,046.73. The aggregate purchase price of the 437,855 shares of Common Stock directly held by the Accounts reported herein was \$6,861,275.19. Further, the securities of the Issuer directly held by the Funds and Accounts were purchased with the working capital of the Funds and Accounts (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business).

Item 4. Purpose of Transaction

Item 4 of this Schedule 13D is supplemented and superseded, as the case may be, as follows:

On February 18, 2026, TSC entered into a cooperation agreement with the Issuer (the "Cooperation Agreement"). Pursuant to the Cooperation Agreement, the Issuer agreed, among other things, to: (i) appoint one independent director following the execution of the Cooperation Agreement and prior to March 15, 2026, (ii) appoint a second independent director prior to, or as soon as reasonably practicable following the 2026 annual meeting of stockholders (the "2026 Annual Meeting"), but in no event later than September 15, 2026, and (iii) appoint a third independent director prior to the 2027 annual meeting of stockholders (the "2027 Annual Meeting"), in each case, in consultation with TSC.

Pursuant to the Cooperation Agreement, the Issuer further agreed that one current director will not be nominated for re-election at the 2027 Annual Meeting. In addition, Jordan Levy, the current Chairman of the Board, has advised the Company that he will not stand for re-election at the 2026 Annual Meeting.

The Cooperation Agreement also includes customary standstill provisions and other obligations, subject to certain exceptions, including (i) restrictions on TSC's ability to acquire additional shares of the Common Stock to the extent such acquisition would cause TSC to beneficially own 9.9% or more of the outstanding Common Stock and (ii) a requirement that TSC vote their shares of Common Stock at the 2026 Annual Meeting and 2027 Annual Meeting in accordance with the Board's recommendations.

The foregoing description of the Cooperation Agreement is qualified by the full text of the Cooperation Agreement, which is included as Exhibit 99.2 to this Amendment No. 7 by reference to Exhibit 10.1 of the Issuer's Current Report on Form 8-K, filed with the SEC on February 18, 2026, and is incorporated by reference herein.

Item 5. Interest in Securities of the Issuer

- (a) Each of the Reporting Persons may be deemed to beneficially own 20,697,679 shares of Common Stock of the Issuer, which includes 313,646 shares of Common Stock issuable upon exercise of warrants and options to purchase 4,465,000 shares of Common Stock. Such amount of beneficial ownership represents approximately 6.7% of the shares of Common Stock outstanding, based on 310,061,300 shares of Common Stock outstanding as of October 20, 2025, based on information disclosed in the Issuer's Form 10-Q filed with the Securities and Exchange Commission ("SEC") on October 24, 2025, plus 313,646 shares of Common Stock issuable upon the exercise of warrants held by the Funds. The Funds and Accounts have delegated to TSC sole voting and investment power over the securities held by the Funds and Accounts pursuant to their respective Investment Management Agreements with TSC. As a result, each of TSC, TSC GP, as the general partner of TSC, and Mr. Toussi, as Chief Investment Officer of TSC and Managing Member of TSC GP, may be deemed to exercise voting and investment power over the securities of the Issuer directly held by the Funds and Accounts. The Funds and Accounts specifically disclaim beneficial ownership of the securities of the Issuer directly held by them by virtue of their inability to vote or dispose of such securities as a result of their respective Investment Management Agreements with TSC. The information in Item 3 regarding the securities held by the Funds and Accounts is incorporated herein by reference.

The options to purchase Common Stock consist of options to purchase 2,965,000 shares of Common Stock held by the Global Fund with an exercise price of \$20 that expire on April 17, 2026, and options to purchase 1,500,000 shares of Common Stock held by the Global Fund with an exercise price of \$18 that expire on March 20, 2026. The Global Fund also has sold options to purchase 1,101,200 shares of Common Stock with an exercise price of \$23 that expire on February 20, 2026; the Global Fund has sold options to purchase 3,577,600 shares of Common Stock with an exercise price of \$22 per share that expire on February 20, 2026; and the Global Fund has sold options to purchase 1,500,000 shares of Common Stock with an exercise price \$23 that expire on March 20, 2026.

- (b) Items 7 through 10 of each of the cover pages of this Schedule 13D are incorporated herein by reference. The information in Item 3 regarding the securities held by the Funds and Accounts is incorporated herein by reference.
- (c) Transactions by the Reporting Persons (on behalf of the Funds and Accounts) effected since the previous amendment to Schedule 13D was filed with the SEC on January 20, 2026, are set forth in Exhibit 99.1 and such information is incorporated herein by reference.
- (d) The disclosure regarding the relationship between the Reporting Persons in Item 2(c) of this Schedule 13D is incorporated herein by reference. All securities reported in this Schedule 13D are directly held by the Funds and Accounts, each of which are investment management clients of TSC. The limited partners of (or investors in) each of the Funds and Accounts have the right to participate in the receipt of dividends from, or proceeds from the sale of, the securities of the Issuer held for the accounts of their respective Funds or Accounts in accordance with their respective limited partnership interests (or investment percentages) in their respective Funds or Accounts.
- (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6 of this Schedule 13D is supplemented and superseded, as the case may be, as follows:

The information in Item 4 of this Schedule 13D is incorporated herein by reference.

The Cooperation Agreement is included as Exhibit 99.2 to this Amendment No. 7 by reference to Exhibit 10.1 of the Issuer's Current Report on Form 8-K, filed with the SEC on February 18, 2026, and is incorporated by reference herein

The information in Item 5 of this Schedule 13D is incorporated herein by reference.

Item 7. Material to be Filed as Exhibits.

99.1 Transactions Effected by the Reporting Persons (on Behalf of the Funds and Accounts) Following January 20, 2026.

99.2 Cooperation Agreement, dated as of February 18, 2026, by and between Core Scientific, Inc and Two Seas Capital LP (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 18, 2026).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Two Seas Capital LP

Signature: /s/ Sina Toussi
Name/Title: Sina Toussi/Managing Member of Two Seas Capital GP LLC, its general partner
Date: 02/19/2026

Two Seas Capital GP LLC

Signature: /s/ Sina Toussi
Name/Title: Sina Toussi/Managing Member
Date: 02/19/2026

Sina Toussi

Signature: /s/ Sina Toussi

Name/Title: Sina Toussi/Self

Date: 02/19/2026

TRANSACTIONS

Except as previously disclosed in this Schedule 13D, as amended, the following table sets forth all transactions by the Reporting Persons (on behalf of the Funds or Accounts) with respect to the securities of Core Scientific, Inc. effected since January 20, 2026, inclusive of any transactions effected through 4:00 p.m., New York City time, on February 19, 2026. Except as otherwise noted below, all such transactions were purchases or sales of securities of Core Scientific, Inc. effected in the open market, and the table excludes commissions paid in per share prices.

TWO SEAS GLOBAL (MASTER) FUND LP

Type of Security	Amount Purchased/(Sold)	Price Per Security (\$) or Contract*	Date of Purchase/Sale
Common Stock	(200,000)	18.400 (1)	1/23/2026
Common Stock	(100,000)	18.600 (2)	1/23/2026
Common Stock	(125,277)	18.835 (3)	1/23/2026
Common Stock	(125,277)	18.879 (4)	1/23/2026
Common Stock	(125,277)	18.974 (5)	1/23/2026
Common Stock	192,421	18.952 (6)	1/26/2026
Common Stock	(83,215)	19.300	1/26/2026
Common Stock	(285,779)	19.544 (7)	1/26/2026
Common Stock	(250,000)	19.250 (8)	1/27/2026
Common Stock	(100,000)	19.450	1/27/2026
Common Stock	(150,000)	19.500	1/27/2026
Common Stock	(100,000)	19.780	1/27/2026
Common Stock	(250,000)	19.800	1/27/2026
Common Stock	(208,038)	19.892 (9)	1/27/2026
Common Stock	(124,822)	19.900	1/27/2026
Common Stock	205,639	19.448 (10)	1/28/2026
Common Stock	287,894	18.927 (11)	1/29/2026
Common Stock	287,894	18.012 (12)	1/30/2026
Common Stock	209,506	14.831 (13)	2/5/2026
Common Stock	(250,000)	15.900 (14)	2/6/2026
Common Stock	(250,000)	16.200	2/6/2026
Common Stock	(122,278)	16.702 (15)	2/6/2026
Call Option (Exercise Price \$17, Expiration 2/20/26)	(15,000) contracts relating to (1,500,000) shares	1.920	2/9/2026
Call Option (Exercise Price \$18, Expiration 3/20/26)	15,000 contracts relating to 1,500,000 shares	2.560	2/9/2026
Call Option (Exercise Price \$23, Expiration 3/20/26)	(15,000) contracts relating to (1,500,000) shares	1.000	2/9/2026
Common Stock	350,000	17.882 (49)	2/19/2026
Call Option (Exercise Price \$17, Expiration 2/20/26)	(35,776) contracts relating to (3,577,600) shares	0.592	2/19/2026
Call Option (Exercise Price \$20, Expiration 4/17/26)	29,650 contracts relating to 2,965,000 shares	1.789	2/19/2026

TWO SEAS STRATEGIC INVESTMENT FUND LP

Type of Security	Amount Purchased/(Sold)	Price Per Security (\$) or Contract*	Date of Purchase/Sale
Common Stock	(22,152)	18.835 (16)	1/23/2026
Common Stock	(22,152)	18.879 (17)	1/23/2026
Common Stock	(22,152)	18.974 (18)	1/23/2026
Common Stock	34,775	18.952 (19)	1/26/2026
Common Stock	(15,039)	19.300	1/26/2026
Common Stock	(51,647)	19.544 (20)	1/26/2026
Common Stock	(37,598)	19.892 (21)	1/27/2026
Common Stock	(22,559)	19.900	1/27/2026
Common Stock	39,747	19.448 (22)	1/28/2026
Common Stock	55,646	18.927 (23)	1/29/2026
Common Stock	55,646	18.012 (24)	1/30/2026
Common Stock	40,494	14.831 (25)	2/5/2026
Common Stock	(23,635)	16.702 (26)	2/6/2026

ACCOUNTS

Type of Security	Amount Purchased/(Sold)	Price Per Security (\$) or Contract*	Date of Purchase/Sale
Common Stock	(1,800)	18,835 (27)	1/23/2026
Common Stock	(1,800)	18,879 (28)	1/23/2026
Common Stock	(1,800)	18,974 (29)	1/23/2026
Common Stock	(771)	18,835 (30)	1/23/2026
Common Stock	(771)	18,879 (31)	1/23/2026
Common Stock	(771)	18,974 (32)	1/23/2026
Common Stock	2,826	18,952 (33)	1/26/2026
Common Stock	(1,222)	19,300	1/26/2026
Common Stock	(4,197)	19,544 (34)	1/26/2026
Common Stock	1,211	18,952 (35)	1/26/2026
Common Stock	(524)	19,300	1/26/2026
Common Stock	(1,798)	19,544 (36)	1/26/2026
Common Stock	(3,055)	19,892 (37)	1/27/2026
Common Stock	(1,833)	19,900	1/27/2026
Common Stock	(1,309)	19,892 (38)	1/27/2026
Common Stock	(786)	19,900	1/27/2026
Common Stock	3,230	19,448 (39)	1/28/2026
Common Stock	1,384	19,448 (40)	1/28/2026
Common Stock	4,522	18,927 (41)	1/29/2026
Common Stock	1,938	18,927 (42)	1/29/2026
Common Stock	4,522	18,012 (43)	1/30/2026
Common Stock	1,938	18,012 (44)	1/30/2026
Common Stock	105,003	14,831 (45)	2/5/2026
Common Stock	44,997	14,831 (46)	2/5/2026
Common Stock	(2,861)	16,702 (47)	2/6/2026
Common Stock	(1,226)	16,702 (48)	2/6/2026

*Prices reflected on a per share basis. Each option is subject to a 100 contract multiplier.

(1) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.35 to \$18.45, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased or sold, as applicable, at each separate price within the ranges set forth in footnotes (1) – (49).

(2) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.60 to \$18.615, inclusive.

(3) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.78 to \$19.18, inclusive.

(4) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.79 to \$19.16, inclusive.

(5) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.95 to \$19.075, inclusive.

(6) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$18.811 to \$19.00, inclusive.

(7) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.50 to \$19.66, inclusive.

(8) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.25 to \$19.28, inclusive.

(9) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.88 to \$19.915, inclusive.

(10) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$19.35 to \$19.50, inclusive.

(11) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$18.77 to \$19.12, inclusive.

(12) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$17.92 to \$18.15, inclusive.

(13) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$14.72 to \$15.00, inclusive.

(14) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.90 to \$15.93, inclusive.

(15) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.365 to \$16.895, inclusive.

(16) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.78 to \$19.18, inclusive.

(17) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.79 to \$19.16, inclusive.

(18) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.95 to \$19.075, inclusive.

(19) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$18.811 to \$19.00, inclusive.

(20) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.50 to \$19.66, inclusive.

